ADDIT-CE NeuroConnect MeetUp 2026 - 2nd edition
Connect, Share, Innovate — 120 seconds at the forefront of Alzheimer's and neurodegenerative diseases
Date: 5th November 2026
Time: 3:00 PM – 6:30 PM (registration from 2:30 PM)
Venue: MultiplexDX, Science Park of Comenius University, Ilkovičova 8, Bratislava
Language: English
Capacity: 100 participants - limited seats
Field: Tackling Alzheimer's, related dementias and other neurodegenerative diseases through research, care, and innovation
Why join?
The first ADDIT-CE NeuroConnect Meetup (Brno, November 2025) brought together 22 pitch presenters and an afternoon of conversations that carried on long after the programme ended. For the second edition, the consortium moves to Bratislava - to the Science Park of Comenius University, home of MultiplexDX.
The format stays deliberately simple: short, sharp presentations followed by open networking. This year, investors will be part of the audience - so your 120 seconds reach not only research partners and clinicians, but also the people who fund what comes next.
What to expect on NeuroConnect Meetup, on 5th November:
- The latest news and upcoming activities from the ADDIT-CE Project,
- Up to 12 short presentations (120 seconds each) from organisations working on diagnostics, therapies, care, digital solutions and investment opportunities,
- The chance to showcase your own project or service in a concise and impactful 120-second pitch, with investors in the audience,
- A collaboration platform: find research partners, technology providers, investors or care innovations,
- Insights into how you can contribute to and benefit from the ADDIT-CE network,
- A look inside MultiplexDX at the Science Park of Comenius University.
Programme:
- 2:30 PM – 3:00 PM | Registration
- 3:00 PM – 3:15 PM | Welcome & ADDIT-CE news
- 3:15 PM – 4:00 PM | 6 short presentations (120s pitches) + investors' questions
- 4:00 PM – 4:15 PM | Coffee & networking break
- 4:15 PM – 5:00 PM | 6 short presentations (120s pitches) + investors' questions
- 5:00 PM – 5:30 PM | Success story (panel discussion)
- 5:30 PM – 6:30 PM | Informal networking & matchmaking
[Detailed programme will be published closer to the event.]
Present your solution in 120 seconds!
Are you developing a new technology, service or research project related to Alzheimer's disease, related dementias or other neurodegenerative diseases? Do you provide care or support services for patients and families? Do you want potential partners, investors or healthcare providers to know about it?
This is your chance.
Simply tick "I want to showcase at the event" in the registration form. 12 slots are available - pitch topics by 16th October 2026. If you'd like to rehearse first, express your interest in the October workshop in the same form.
Why should you participate in the presentation and take the stage?
The best pitch will win a free consultation with one of the investors - get expert advice tailored to your project!
REGISTER NOW AND SAVE A SPOT
Do you want to attend but don't want to present on the stage?
Not problem at all - we would love to see you in the audience, just reserve your seat using our event registration form, and be right in the middle of the action.
What's new in 2026: get ready for your presentation with the "Science for Investors" training webinar!
Investors are not your peers. They do not need your methodology - they need the problem, the customer, and why you are the one to solve it.
Bring a project, even an early-stage one. You'll leave with a draft opening, a defined ask, and a clear next step.
That's why this year's meetup comes with an optional preparation step:
- When: 8th October 2026, 3:00 PM – 5:00 PM (CEST)
- Where: ONLINE
- Who is invited: pitch presenters and others who are interested
- Language: English
- What you get: A practical two-hour webinar on turning research into a story that gets funded. We'll cover the anatomy of an investor pitch with a live before/after rewrite, the six levels of "the ask" (from advice to investment), and how to build slides for this audience - headline as takeaway, one number per slide, the two-deck principle. The second half is hands-on: draft your own hook and ask, then test them in a practice round with feedback.
How to sign up: Indicate your interest in our event registration form, and we will confirm your place by e-mail. Please express your interest by 7th October 2026.
Who should attend?
- Researchers & clinicians,
- Companies developing diagnostics, therapies or digital solutions,
- Care providers & NGOs,
- Investors & funding organisations,
- Students & innovators,
- Anyone committed to advancing research, care and innovation in Alzheimer's disease, related dementias and other neurodegenerative diseases.
REGISTER NOW FOR THE EVENT
About ADDIT-CE
ADDIT-CE - Alzheimer's Disease Diagnostics Innovation and Translation to Clinical Practice in Central Europe - connects research teams from CEITEC MU, Faculty of Science MU, Faculty of Medicine MU, FNUSA, the Biomedical Centre SAS and the Institute of Neuroimmunology SAS with the biotechnology companies BioVendor, MultiplexDX and Geneton. Its mission is to link the research and innovation ecosystems of the Brno and Bratislava regions, modernise Alzheimer's diagnostics and transfer new technologies into clinical practice.
This event has received funding from the European Union's Horizon Europe programme under Grant Agreement No. 101087124. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.
If you have any questions, contact us: events@multiplexdx.com
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
